- Crizalk 250mg belongs to type of tyrosine kinase inhibitor. Kinases are enzymes which are included in many functions, involving cell development and reproduction.
- Crizalk 250mg is made specifically for the treatment of a type of lung cancer in which ALK is overactive due to an abnormality in the ALK gene.
- Crizalk 250mg capsule is a prescription drug which is used under the supervision of medical practioner.
INDICATION
- Crizalk 250mg capsule is indicated for the therapy of patients having metastatic non-small cell lung cancer.
DOSAGE MODIFICATION
- Crizalk 250mg taken orally twice daily for First dose reduction
- Crizalk 250mg taken orally once daily for Second dose reduction
- Permanently discontinue if unable to tolerate Crizalk 250 mg taken orally once daily.
MECHANISM
- Particularly, crizotinibprevents anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR, c-MET), and Recepteurd’OrigineNantais (RON).
- Malformations in the ALK gene result by mutations or translocations may leads expression of oncogenic fusion proteins. somepatients with NSCLC, they have the EML4-ALK gene.
- Crizotinib inhibits ALK tyrosine kinase which essentially results in decreased proliferation of cells which carry the genetic mutation and tumour survivability.
ADME
- Maximum serum concentration is 4 to 6 hours and bioavailability were 43%.
- Volume of distribution is 1772L and plasma protein bounding is 91%
- Crizalk metabolised by CYP3A4 and CYP3A5
- Crizalk is eliminated via feces 63% and 22% via urine and half -life is 42 hours
Dosage and administration :
- Select patients for the treatment with Crizalk 250mg based on ALK or ROS1 presences in tumor specimens
- The usual dosage of Crizalk is 250mg orally twice in a day
- Administer the Crizalk dose with or without food, until disease progression.
PRECAUTION
- Before using Crizalk in some condition, consult with doctor.
- Hepatotoxicity causes while treatment with Crizalk 250mg.
- while treatment with Crizalk will causes Interstitial lung disease/pneumonitis.
- QT interval prolongation
- Bradycardia
- Severe visual loss
Embryo-fetal toxicity:
- based on mechanism action the drug will cause risk to foetus
DRUG INTERACTION
- Crizalk 250mg Combination with strong or moderate CYP3A4 inhibitors will increase Crizalk plasma concentration
- Crizalk 250mg concomitant use with strong CYP3A inducers will decrease Crizotinib plasma concentration
- Crizalk 250mg capsule Interaction with CYP3A substrates will increase plasma concentration of CYP3A substrates
- Do not use combination with bradycardia causing drugs
CONTRAINDICATION
- None
MISSED DOSE
- If the patient vomits after taking a dose of Crizalk 250mg or missed to take a dose, then should not to take an extra dose, but to take the next dose at the regular time, skip the missed dose.
STORAGE
- Store at 20℃ to 25℃
SIDE EFFECTS
Crizalk is caused some side effects as follows :
- Infection increased
- Breathlessness
- Eyesight changes
- Bowel changes
- Feeling sick
- Swelling of hands and feet’s
- Decreased appetite
- Fatigue
- Liver changes
- Skin rash
- bradycardia.
CONTACT DETAILS
Phone: + 91-9987711567
Email: applepharmaceutical@gmail.com
Email: info@myapplepharma.com
katherine 